I don't think PYC is involved in this case as the Roche collaboration still remains on intracellular pathways & for delivery across the blood-brain barrier against neurological disease targets.
The article is in referance to Roche/Genetechs collaboration with Curis whom are also a drug development company & heavily focussed on the SHH pathway -interesting company though.
Will be interesting to see what's going on with Sonic & Phylogica though, i wonder if this will be kept internal or it will go out through Phenomica as I'm pretty sure alot of the work was being undertaken with MRC Hutchinson in the UK ?
PYC Price at posting:
5.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)